Flecainide Should Not Be Increased for Rate Control in Atrial Fibrillation
Flecainide is not a rate-control agent and increasing its dose will not effectively control ventricular rate in atrial fibrillation. Flecainide is a class IC antiarrhythmic drug designed for rhythm control (maintaining sinus rhythm), not rate control of the ventricular response during atrial fibrillation 1.
Mechanism and Indication
Flecainide functions as a potent sodium channel blocker that slows atrial conduction and prolongs atrial action potential duration, making it effective for preventing AF recurrence but ineffective for controlling ventricular rate during active AF 1.
The drug is indicated for rhythm control in paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia, with a starting dose of 50 mg every 12 hours that may be increased to a maximum of 300 mg/day for supraventricular arrhythmias 2.
Flecainide approximately doubles the likelihood of maintaining sinus rhythm but does not provide rate control during active atrial fibrillation 3.
Critical Safety Concerns with Dose Escalation
Increasing flecainide doses carries significant proarrhythmic risk, particularly the development of monomorphic ventricular tachycardia, not torsades de pointes 1.
The Cardiac Arrhythmia Suppression Trial (CAST) demonstrated that flecainide increased total mortality and risk of nonfatal cardiac arrest, particularly in patients with structural heart disease, ventricular conduction delays (QRS >120 ms), or left ventricular dysfunction 1.
Higher initial doses and rapid dosage adjustments have resulted in increased incidence of proarrhythmic events and congestive heart failure, particularly during the first few days of dosing 2.
Contraindications That Preclude Use
Flecainide is absolutely contraindicated in patients with:
- Heart failure with reduced ejection fraction (NYHA class II-IV or LVEF <30%) 1
- Coronary artery disease or history of myocardial infarction 1, 3, 1
- Structural heart disease 1
- Significant left ventricular hypertrophy 3, 4
- Ventricular scar tissue 1
Appropriate Rate-Control Strategy
For rate control in atrial fibrillation, use AV nodal blocking agents instead:
First-Line Options (Hemodynamically Stable, No Heart Failure)
- Beta-blockers (e.g., metoprolol 2.5-5 mg IV bolus) or nondihydropyridine calcium channel blockers (e.g., diltiazem 0.25 mg/kg IV) are recommended for rapid ventricular rate control 5.
Heart Failure or LV Dysfunction
- Intravenous digoxin or amiodarone should be used instead of calcium channel blockers, which may worsen hemodynamics 6, 5.
- Digoxin loading: 0.25-0.5 mg IV over several minutes, with repeat 0.25 mg doses every 6 hours as needed 6.
Rate-Control Target
- Initial lenient rate control target of resting heart rate <110 bpm is appropriate, tightening only if symptoms persist 5.
Monitoring Requirements If Flecainide Is Used for Rhythm Control
Regular ECG monitoring is mandatory; an increase in QRS duration of ≥25% compared to baseline indicates potential proarrhythmic risk and requires dose reduction or discontinuation 3.
Concomitant AV nodal blockade (beta-blocker or calcium channel blocker) is recommended because flecainide can convert AF to atrial flutter with rapid 1:1 ventricular conduction 3.
Plasma trough flecainide levels should be monitored, with therapeutic levels of 200-500 ng/mL 2.
Clinical Efficacy Data
In clinical trials, flecainide prevented recurrent AF in 31% of patients but was associated with cardiac adverse events in 11% of patients, with higher rates in those with chronic atrial fibrillation and structural heart disease 7.
Approximately one-third of patients discontinue flecainide therapy, most commonly due to adverse drug effects, particularly proarrhythmic effects (48% of discontinuations) 8.